Stoke Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-104.7	-101.07	-85.81	-52.24	-32.33	-12.52	-5.56
Depreciation & Amortization	4.73	3.54	2.23	1.93	0.45	0.21	0.11
Share-Based Compensation	25.26	22.85	16.45	5.77	1.92	0.24	0.03
Other Operating Activities	-6.35	42.81	0.22	2.33	-1.1	1.1	-0.14
Operating Cash Flow	-81.07	-31.87	-66.91	-42.22	-31.06	-10.96	-5.56
Capital Expenditures	-1.62	-3.96	-1.2	-1.05	-1.63	-0.93	-0.11
Change in Investments	107.56	-41.92	-75.23	0	0	0	0
Investing Cash Flow	105.95	-45.88	-76.43	-1.05	-1.63	-0.93	-0.11
Share Issuance / Repurchase	53.01	46.41	1.29	108.59	152.23	0.02	0
Other Financing Activities	-	0	-0	-0.49	-2.47	115.62	5.97
Financing Cash Flow	53.01	46.41	1.28	108.11	149.76	115.64	5.97
Net Cash Flow	77.89	-31.34	-142.05	64.84	117.07	103.75	0.48
Free Cash Flow	-82.68	-35.83	-68.11	-43.27	-32.69	-11.89	-5.67
Free Cash Flow Margin	-941.72%	-288.82%	-	-	-	-	-
Free Cash Flow Per Share	-1.88	-0.92	-1.85	-1.29	-1.82	-16.76	-8.46

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).